The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA Cancer J Clin2016;66:730.

  • 2.

    MochHGasserTAminMB. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer2000;89:604614.

    • Search Google Scholar
    • Export Citation
  • 3.

    LeibovichBCLohseCMCrispenPL. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol2010;183:13091315.

    • Search Google Scholar
    • Export Citation
  • 4.

    ChoykePLGlennGMWaltherMM. Hereditary renal cancers. Radiology2003;226:3346.

  • 5.

    DeVitaVTJrLawrenceTSRosenbergSA. Cancer: Principles & Practice of Oncology8th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 6.

    Cancer Stat Fact: Kidney and Renal Pelvis Cancer. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html.

  • 7.

    FicarraVSchipsLGuilleF. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer2005;104:968974.

    • Search Google Scholar
    • Export Citation
  • 8.

    FrankIBluteMLLeibovichBC. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol2005;173:18891892.

    • Search Google Scholar
    • Export Citation
  • 9.

    ZismanAPantuckAJChaoD. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol2001;166:5458.

    • Search Google Scholar
    • Export Citation
  • 10.

    KlatteTPatardJJGoelRH. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol2007;178:3540; discussion 40.

    • Search Google Scholar
    • Export Citation
  • 11.

    LamJSKlatteTPatardJJ. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol2007;52:155162.

    • Search Google Scholar
    • Export Citation
  • 12.

    MinerviniALilasLMinerviniRSelliC. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer2002;94:25902595.

    • Search Google Scholar
    • Export Citation
  • 13.

    Dall'OglioMFAntunesAASarkisAS. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int2007;100:552555.

    • Search Google Scholar
    • Export Citation
  • 14.

    Dall'OglioMFRibeiro-FilhoLAAntunesAA. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol2007;178:425428; discussion 428.

    • Search Google Scholar
    • Export Citation
  • 15.

    LamJSShvartsOSaidJW. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer2005;103:25172525.

    • Search Google Scholar
    • Export Citation
  • 16.

    SenguptaSLohseCMLeibovichBC. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer2005;104:511520.

    • Search Google Scholar
    • Export Citation
  • 17.

    JaysonMSandersH. Increased incidence of serendipitously discovered renal cell carcinoma. Urology1998;51:203205.

  • 18.

    LucianiLGCestariRTallarigoC. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology2000;56:5862..

    • Search Google Scholar
    • Export Citation
  • 19.

    ShuchBVourgantiSRickettsCJ. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol2014;32:431437.

    • Search Google Scholar
    • Export Citation
  • 20.

    IsraelGMBosniakMA. How I do it: evaluating renal masses. Radiology2005;236:441450.

  • 21.

    LimDJCarterMF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol1993;150:11121114.

    • Search Google Scholar
    • Export Citation
  • 22.

    MilesD. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Cancer2014;22:679687.

    • Search Google Scholar
    • Export Citation
  • 23.

    ShethSScatarigeJCHortonKM. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics2001;21(Spec No):237254.

    • Search Google Scholar
    • Export Citation
  • 24.

    HricakHDemasBEWilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 25.

    JanusCLMendelsonDS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging1991;32:69118.

  • 26.

    SeamanEGoluboffETRossSSawczukIS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology1996;48:692695.

    • Search Google Scholar
    • Export Citation
  • 27.

    ShannonBACohenRJde BrutoHDaviesRJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol2008;180:12571261; discussion 1261.

    • Search Google Scholar
    • Export Citation
  • 28.

    ParkJWJoMKLeeHM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int2009;103:615619.

    • Search Google Scholar
    • Export Citation
  • 29.

    AJCC Cancer Staging ManualSeventh Edition (2010) published by Springer Science+Business Media, LLC (SBM).

  • 30.

    EbleJNSauterGEpsteinJI eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.

    • Search Google Scholar
    • Export Citation
  • 31.

    BergerABrandinaRAtallaMA. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol2009;182:21722176.

    • Search Google Scholar
    • Export Citation
  • 32.

    BurgessNAKooBCCalvertRC. Randomized trial of laparoscopic v open nephrectomy. J Endourol2007;21:610613.

  • 33.

    ChungSDHuangKHLaiMK. Long-term follow-up of hand-assisted laparoscopic radical nephrectomy for organ-confined renal cell carcinoma. Urology2007;69:652655.

    • Search Google Scholar
    • Export Citation
  • 34.

    GabrAHGdorYStropeSA. Patient and pathologic correlates with perioperative and long-term outcomes of laparoscopic radical nephrectomy. Urology2009;74:635640.

    • Search Google Scholar
    • Export Citation
  • 35.

    HemalAKKumarA. A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. World J Urol2009;27:8994.

    • Search Google Scholar
    • Export Citation
  • 36.

    HemalAKKumarAKumarR. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol2007;177:862866.

    • Search Google Scholar
    • Export Citation
  • 37.

    LuoJHZhouFJXieD. Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy. World J Urol2010;28:289293.

    • Search Google Scholar
    • Export Citation
  • 38.

    NambirajanTJeschkeSAl-ZahraniH. Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. Urology2004;64:919924.

    • Search Google Scholar
    • Export Citation
  • 39.

    DashAVickersAJSchachterLR. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int2006;97:939945.

    • Search Google Scholar
    • Export Citation
  • 40.

    LauWKBluteMLWeaverAL. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc2000;75:12361242.

    • Search Google Scholar
    • Export Citation
  • 41.

    LeeCTKatzJShiW. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol2000;163:730736.

  • 42.

    LeibovichBCBluteMLChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;171:10661070.

    • Search Google Scholar
    • Export Citation
  • 43.

    ZiniLPerrottePCapitanioU. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer2009;115:14651471.

  • 44.

    LeeHJLissMADerweeshIH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol2014;24:448452.

  • 45.

    HuangWCLeveyASSerioAM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol2006;7:735740.

    • Search Google Scholar
    • Export Citation
  • 46.

    GoASChertowGMFanD. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004;351:12961305.

    • Search Google Scholar
    • Export Citation
  • 47.

    ThompsonRHBoorjianSALohseCM. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol2008;179:468471; discussion 472–463.

    • Search Google Scholar
    • Export Citation
  • 48.

    WeightCJLieserGLarsonBT. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol2010;58:293298.

    • Search Google Scholar
    • Export Citation
  • 49.

    WeightCJLarsonBTGaoT. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology2010;76:631637.

    • Search Google Scholar
    • Export Citation
  • 50.

    KimSPThompsonRHBoorjianSA. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol2012;188:5157.

    • Search Google Scholar
    • Export Citation
  • 51.

    ThompsonRHSiddiquiSLohseCM. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol2009;182:26012606.

  • 52.

    HollingsworthJMMillerDCDunnRL. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 53.

    ShuchBLamJSBelldegrunAS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep2006;7:3138.

  • 54.

    ChenDYUzzoRG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw2009;7:635642; quiz 643.

    • Search Google Scholar
    • Export Citation
  • 55.

    TanHJNortonECYeZ. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA2012;307:16291635.

    • Search Google Scholar
    • Export Citation
  • 56.

    GillISKavoussiLRLaneBR. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol2007;178:4146.

    • Search Google Scholar
    • Export Citation
  • 57.

    GongEMOrvietoMAZornKC. Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. J Endourol2008;22:953957..

    • Search Google Scholar
    • Export Citation
  • 58.

    LaneBRGillIS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol2010;183:473479.

  • 59.

    FunahashiYHattoriRYamamotoT. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol2009;55:209215.

    • Search Google Scholar
    • Export Citation
  • 60.

    BlomJHvan PoppelHMarechalJM. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol2009;55:2834.

    • Search Google Scholar
    • Export Citation
  • 61.

    BluteMLLeibovichBCChevilleJC. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol2004;172:465469.

    • Search Google Scholar
    • Export Citation
  • 62.

    CapitanioUBeckerFBluteML. Lymph node dissection in renal cell carcinoma. Eur Urol2011;60:12121220.

  • 63.

    KuczykMMunchTMachtensS. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int2002;89:517522.

    • Search Google Scholar
    • Export Citation
  • 64.

    KuczykMWegenerGJonasU. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol2005;48:252257.

    • Search Google Scholar
    • Export Citation
  • 65.

    O'MalleyRLGodoyGKanofskyJATanejaSS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol2009;181:20092017.

    • Search Google Scholar
    • Export Citation
  • 66.

    LaneBRTiongHYCampbellSC. Management of the adrenal gland during partial nephrectomy. J Urol2009;181:24302436; discussion 2436–2437.

    • Search Google Scholar
    • Export Citation
  • 67.

    Rais-BahramiSGuzzoTJJarrettTW. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int2009;103:13551358.

    • Search Google Scholar
    • Export Citation
  • 68.

    AbouassalyRLaneBRNovickAC. Active surveillance of renal masses in elderly patients. J Urol2008;180:505508; discussion 508–509.

  • 69.

    LaneBRAbouassalyRGaoT. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer2010;116:31193126.

    • Search Google Scholar
    • Export Citation
  • 70.

    BirdVGCareyRIAyyathuraiRBirdVY. Management of renal masses with laparoscopic-guided radiofrequency ablation versus laparoscopic partial nephrectomy. J Endourol2009;23:8188.

    • Search Google Scholar
    • Export Citation
  • 71.

    CampbellSCNovickACBelldegrunA. Guideline for management of the clinical T1 renal mass. J Urol2009;182:12711279.

  • 72.

    KunkleDAUzzoRG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer2008;113:26712680.

  • 73.

    O'MalleyRLBergerADKanofskyJA. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. BJU Int2007;99:395398.

    • Search Google Scholar
    • Export Citation
  • 74.

    SimmonsMNWeightCJGillIS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology2009;73:10771082.

    • Search Google Scholar
    • Export Citation
  • 75.

    PeycelonMHupertanVComperatE. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol2009;181:3541.

    • Search Google Scholar
    • Export Citation
  • 76.

    EggenerSEYossepowitchOPettusJA. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol2006;24:31013106.

    • Search Google Scholar
    • Export Citation
  • 77.

    StewartSBThompsonRHPsutkaSP. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines. J Clin Oncol2014.

    • Search Google Scholar
    • Export Citation
  • 78.

    MucksavagePKutikovAMagerfleischL. Comparison of radiographical imaging modalities for measuring the diameter of renal masses: is there a sizeable difference?BJU Int2011;108:E232236.

    • Search Google Scholar
    • Export Citation
  • 79.

    SmaldoneMCFungCUzzoRGHaasNB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am2011;25:765791.

    • Search Google Scholar
    • Export Citation
  • 80.

    HaasNBManolaJUzzoRG. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016;387:20082016.

    • Search Google Scholar
    • Export Citation
  • 81.

    GillISKavoussiLRLaneBR. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol2007;178:4146.

    • Search Google Scholar
    • Export Citation
  • 82.

    HerrHW. Partial nephrectomy for incidental renal cell carcinoma. Br J Urol1994;74:431433.

  • 83.

    MorganWRZinckeH. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol1990;144:852857.

    • Search Google Scholar
    • Export Citation
  • 84.

    AdamyAChongKTChadeD. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol2011;185:433438.

    • Search Google Scholar
    • Export Citation
  • 85.

    LamJSShvartsOLeppertJT. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol2005;174:466472; discussion 472; quiz 801.

    • Search Google Scholar
    • Export Citation
  • 86.

    MotzerRJBacikJMurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 87.

    MekhailTMAbou-JawdeRMBoumerhiG. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol2005;23:832841.

    • Search Google Scholar
    • Export Citation
  • 88.

    HengDYXieWReganMM. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol2009;27:57945799.

    • Search Google Scholar
    • Export Citation
  • 89.

    HengDYXieWReganMM. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol2013;14:141148.

    • Search Google Scholar
    • Export Citation
  • 90.

    FlaniganRCMickischGSylvesterR. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 91.

    FlaniganRCSalmonSEBlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 92.

    MickischGHGarinAvan PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 93.

    PolcariAJGorbonosAMilnerJEFlaniganRC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol2009;16:227233.

    • Search Google Scholar
    • Export Citation
  • 94.

    CulpSHTannirNMAbelEJ. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?Cancer2010;116:33783388.

    • Search Google Scholar
    • Export Citation
  • 95.

    LeibovichBCHanKRBuiMH. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer2003;98:25662575.

    • Search Google Scholar
    • Export Citation
  • 96.

    ChoueiriTKXieWKollmannsbergerC. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol2011;185:6066.

    • Search Google Scholar
    • Export Citation
  • 97.

    RosenbergSAMuleJJSpiessPJ. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med1985;161:11691188.

    • Search Google Scholar
    • Export Citation
  • 98.

    DutcherJPFisherRIWeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 99.

    NegrierSEscudierBLassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med1998;338:12721278.

    • Search Google Scholar
    • Export Citation
  • 100.

    FyfeGFisherRIRosenbergSA. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol1995;13:688696.

    • Search Google Scholar
    • Export Citation
  • 101.

    McDermottDFReganMMClarkJI. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol2005;23:133141.

    • Search Google Scholar
    • Export Citation
  • 102.

    MotzerRJHutsonTETomczakP. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009;27:35843590.

    • Search Google Scholar
    • Export Citation
  • 103.

    YangJCSherryRMSteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 104.

    LeibovichBCBluteMLChevilleJC. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer2003;97:16631671.

    • Search Google Scholar
    • Export Citation
  • 105.

    SternbergCNDavisIDMardiakJ. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 106.

    SternbergCNHawkinsREWagstaffJ. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer2013;49:12871296..

    • Search Google Scholar
    • Export Citation
  • 107.

    MotzerRJHutsonTECellaD. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med2013;369:722731.

  • 108.

    MotzerRJHutsonTEMcCannL. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med2014;370:17691770.

  • 109.

    EscudierBJPortaCBonoP. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310 [abstract]. J Clin Oncol2012;30(Suppl):Abstract CRA4502.

    • Search Google Scholar
    • Export Citation
  • 110.

    MotzerRJHutsonTETomczakP. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007;356:115124.

  • 111.

    MotzerRJMichaelsonMDRedmanBG. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol2006;24:1624.

    • Search Google Scholar
    • Export Citation
  • 112.

    ChowLQEckhardtSG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol2007;25:884896.

  • 113.

    FaivreSDelbaldoCVeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 114.

    GoreMESzczylikCPortaC. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer2015;113:1219.

    • Search Google Scholar
    • Export Citation
  • 115.

    Ruiz-MoralesJMSwierkowskiMWellsJC. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer2016;65:102108.

    • Search Google Scholar
    • Export Citation
  • 116.

    EscudierBPluzanskaAKoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 117.

    RiniBIChoueiriTKElsonP. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer2008;113:13091314.

  • 118.

    RiniBIHalabiSRosenbergJE. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol2010;28:21372143.

    • Search Google Scholar
    • Export Citation
  • 119.

    HudesGCarducciMTomczakP. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007;356:22712281.

  • 120.

    AwadaAHendliszAGilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 121.

    ClarkJWEderJPRyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 122.

    MooreMHirteHWSiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 123.

    StrumbergDRichlyHHilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 124.

    WilhelmSMCarterCTangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 125.

    EscudierBSzczylikCHutsonTE. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol2009;27:12801289.

    • Search Google Scholar
    • Export Citation
  • 126.

    HutsonTELesovoyVAl-ShukriS. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol2013;14:12871294.

    • Search Google Scholar
    • Export Citation
  • 127.

    RiniBIMelicharBUedaT. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol2013;14:12331242.

    • Search Google Scholar
    • Export Citation
  • 128.

    ChoueiriTKEscudierBPowlesT. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015;373:18141823.

  • 129.

    ChoueiriTKEscudierBPowlesT. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016;17:917927.

    • Search Google Scholar
    • Export Citation
  • 130.

    MotzerRJEscudierBMcDermottDF. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015;373:18031813.

  • 131.

    MotzerRJSharmaPMcDermottDF. CheckMate 025 phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol2016;34(Suppl):Abstract 498.

    • Search Google Scholar
    • Export Citation
  • 132.

    CellaDEscudierBRiniB. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer2013;108:15711578.

    • Search Google Scholar
    • Export Citation
  • 133.

    EscudierBJMotzerRJSharmaP. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study [abstract]. J Clin Oncol2016;34(Suppl):Abstract 4509.

    • Search Google Scholar
    • Export Citation
  • 134.

    MotzerRJHutsonTEGlenH. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol2015;16:14731482.

    • Search Google Scholar
    • Export Citation
  • 135.

    MotzerRJHutsonTERenM. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol2016;17:e45.

    • Search Google Scholar
    • Export Citation
  • 136.

    SonpavdeGHutsonTERiniBI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs2008;17:741748.

  • 137.

    RiniBIEscudierBTomczakP. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet2011;378:19311939.

    • Search Google Scholar
    • Export Citation
  • 138.

    MotzerRJEscudierBTomczakP. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol2013;14:552562.

    • Search Google Scholar
    • Export Citation
  • 139.

    RiniBIde La Motte RougeTHarzstarkAL. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer2013;11:107114.

    • Search Google Scholar
    • Export Citation
  • 140.

    MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 141.

    MotzerRJEscudierBOudardS. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer2010;116:42564265.

    • Search Google Scholar
    • Export Citation
  • 142.

    EscudierBEisenTStadlerWM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007;356:125134.

  • 143.

    EscudierBEisenTStadlerWM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol2009;27:33123318.

    • Search Google Scholar
    • Export Citation
  • 144.

    Di LorenzoGCarteniGAutorinoR. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol2009;27:44694474.

    • Search Google Scholar
    • Export Citation
  • 145.

    GarciaJAHutsonTEElsonP. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer2010;116:53835390.

    • Search Google Scholar
    • Export Citation
  • 146.

    MotzerRJRiniBIBukowskiRM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA2006;295:25162524.

  • 147.

    DudekAZZolnierekJDhamA. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer2009;115:6167.

  • 148.

    EichelbergCHeuerRChunFK. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol2008;54:13731378.

    • Search Google Scholar
    • Export Citation
  • 149.

    SablinMPNegrierSRavaudA. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol2009;182:2934; discussion 34.

  • 150.

    ShepardDRRiniBIGarciaJA. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol2008;26(Suppl):Abstract 5123.

    • Search Google Scholar
    • Export Citation
  • 151.

    ZimmermannKSchmittelASteinerU. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology2009;76:350354.

    • Search Google Scholar
    • Export Citation
  • 152.

    HainsworthJDRubinMSArrowsmithER. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer2013;11:270275.

    • Search Google Scholar
    • Export Citation
  • 153.

    MatranaMRDuranCShettyA. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer2013;49:31693175.

    • Search Google Scholar
    • Export Citation
  • 154.

    YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427434.

    • Search Google Scholar
    • Export Citation
  • 155.

    AtkinsMBHidalgoMStadlerWM. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol2004;22:909918.

    • Search Google Scholar
    • Export Citation
  • 156.

    HutsonTEEscudierBEstebanE. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol2014;32:760767.

    • Search Google Scholar
    • Export Citation
  • 157.

    HwangCHeathEI. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. J Clin Oncol2014;32:729734.

  • 158.

    EscudierBMichaelsonMDMotzerRJ. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer2014;110:28212828.

    • Search Google Scholar
    • Export Citation
  • 159.

    MotzerRJBarriosCHKimTM. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol2014;32:27652772.

    • Search Google Scholar
    • Export Citation
  • 160.

    GoreMESzczylikCPortaC. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol2009;10:757763.

    • Search Google Scholar
    • Export Citation
  • 161.

    ChoueiriTKPlantadeAElsonP. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol2008;26:127131.

    • Search Google Scholar
    • Export Citation
  • 162.

    TannirNMPlimackENgC. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol2012;62:10131019.

    • Search Google Scholar
    • Export Citation
  • 163.

    PlimackERJonaschEBekeleBN. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study [abstract]. J Clin Oncol2010;28(Suppl):Abstract 4604.

    • Search Google Scholar
    • Export Citation
  • 164.

    RavaudAOudardSGravis-MescamG. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract]. J Clin Oncol2009;27(Suppl):Abstract 5146

    • Search Google Scholar
    • Export Citation
  • 165.

    LeeJLAhnJHLimHY. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol2012;23:21082114.

    • Search Google Scholar
    • Export Citation
  • 166.

    MolinaAMFeldmanDRGinsbergMS. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs2012;30:335340. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20711632.

    • Search Google Scholar
    • Export Citation
  • 167.

    ShiHZTianJLiCL. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma. Asia Pac J Clin Oncol2015;11:328333.

    • Search Google Scholar
    • Export Citation
  • 168.

    ArmstrongAJBroderickSEisenT. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN) [abstract]. J Clin Oncol2015;33(Suppl):Abstract 4507.

    • Search Google Scholar
    • Export Citation
  • 169.

    TannirNMJonaschEAlbigesL. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol2016;69:866874.

    • Search Google Scholar
    • Export Citation
  • 170.

    DutcherJPde SouzaPMcDermottD. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol2009;26:202209.

    • Search Google Scholar
    • Export Citation
  • 171.

    VenugopalBAnsariJAitchisonM. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol2013;13:26.

  • 172.

    BlankCUBonoPLarkinJMG. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: subgroup analysis of REACT [abstract]. J Clin Oncol2012;30(Suppl):Abstract 402.

    • Search Google Scholar
    • Export Citation
  • 173.

    LarkinJMFisherRAPickeringLM. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol2011;29:e241242.

    • Search Google Scholar
    • Export Citation
  • 174.

    KohYKimJYLimHY. Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology [abstract]. J Clin Oncol2012;30(Suppl):Abstract 4544.

    • Search Google Scholar
    • Export Citation
  • 175.

    StadlerWMFiglinRAMcDermottDF. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer2010;116:12721280.

    • Search Google Scholar
    • Export Citation
  • 176.

    BeckJProcopioGBajettaE. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol2011;22:18121823.

    • Search Google Scholar
    • Export Citation
  • 177.

    UnnithanJVaziriSWoodDPJr. Characterization of type II papillary renal cell carcinoma and efficacy of sorafenib [abstract]. Presented at the 2008 Genitourinary Cancers Symposium; February14–162008; San Francisco, California. Abstract 409.

    • Search Google Scholar
    • Export Citation
  • 178.

    ButiSBersanelliMMainesF. First-line pazopanib in non-clear cell renal carcinoma: the Italian retrospective multicenter PANORAMA study [abstract].J Clin Oncol2016;34(Suppl):Abstract e16081.

    • Search Google Scholar
    • Export Citation
  • 179.

    GordonMSHusseyMNagleRB. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol2009;27:57885793.

    • Search Google Scholar
    • Export Citation
  • 180.

    IrshadTOlenckiTZyngerDL. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC) [abstract]. J Clin Oncol2011;29(Suppl):Abstract e15158.

    • Search Google Scholar
    • Export Citation
  • 181.

    ChowdhurySMatranaMRTsangC. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am2011;25:853869.

    • Search Google Scholar
    • Export Citation
  • 182.

    PatardJJLerayERioux-LeclercqN. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol2005;23:27632771.

    • Search Google Scholar
    • Export Citation
  • 183.

    ChevilleJCLohseCMZinckeH. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol2003;27:612624.

    • Search Google Scholar
    • Export Citation
  • 184.

    ChevilleJCLohseCMZinckeH. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol2004;28:435441.

    • Search Google Scholar
    • Export Citation
  • 185.

    ShuchBBratslavskyGLinehanWMSrinivasanR. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist2012;17:4654.

    • Search Google Scholar
    • Export Citation
  • 186.

    NanusDMGarinoAMilowskyMI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 187.

    DutcherJPNanusD. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol2011;28:15301533.

    • Search Google Scholar
    • Export Citation
  • 188.

    HaasNBLinXManolaJ. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol2012;29:761767.

    • Search Google Scholar
    • Export Citation
  • 189.

    RicheySLNgCLimZD. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol2011;29:e203205.

    • Search Google Scholar
    • Export Citation
  • 190.

    TannirNMThallPFNgCS. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol2008;180:867872; discussion 872.

    • Search Google Scholar
    • Export Citation
  • 191.

    StadlerWMHalabiSRiniB. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer2006;107:12731279.

    • Search Google Scholar
    • Export Citation
  • 192.

    MichaelsonMDMcKayRRWernerL. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer2015;121:34353443.

    • Search Google Scholar
    • Export Citation
  • 193.

    HakimiAAKoiPTMilhouaPM. Renal medullary carcinoma: the Bronx experience. Urology2007;70:878882.

  • 194.

    WatanabeICBillisAGuimaraesMS. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol2007;20:914920.

  • 195.

    SrigleyJRDelahuntB. Uncommon and recently described renal carcinomas. Mod Pathol2009;22(Suppl 2):S223.

  • 196.

    TokudaNNaitoSMatsuzakiO. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol2006;176:4043; discussion 43.

    • Search Google Scholar
    • Export Citation
  • 197.

    KarakiewiczPITrinhQDRioux-LeclercqN. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol2007;52:11401145.

    • Search Google Scholar
    • Export Citation
  • 198.

    GuptaRBillisAShahRB. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol2012;36:12651278.

    • Search Google Scholar
    • Export Citation
  • 199.

    OudardSBanuEVieillefondA. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol2007;177:16981702.

    • Search Google Scholar
    • Export Citation
  • 200.

    FokasEHenzelMHammK. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol2010;186:210217.

    • Search Google Scholar
    • Export Citation
  • 201.

    ZekriJAhmedNColemanREHancockBW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol2001;19:379382.

  • 202.

    Schlesinger-RaabATreiberUZaakD. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer2008;44:24852495.

    • Search Google Scholar
    • Export Citation
  • 203.

    RozaTHakimLvan PoppelHJoniauS. Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. Drugs Aging2013;30:877886.

    • Search Google Scholar
    • Export Citation
  • 204.

    HunterGKBalagamwalaEHKoyfmanSA. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol2012;2:e95100.

    • Search Google Scholar
    • Export Citation
  • 205.

    ZelefskyMJGrecoCMotzerR. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys2012;82:17441748.

    • Search Google Scholar
    • Export Citation
  • 206.

    LiptonAZhengMSeamanJ. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer2003;98:962969.

    • Search Google Scholar
    • Export Citation
  • 207.

    RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:26132621.

    • Search Google Scholar
    • Export Citation
  • 208.

    HenryDHCostaLGoldwasserF. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol2011;29:11251132.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 2818 2818 179
PDF Downloads 781 781 68
EPUB Downloads 0 0 0